Amarin Q3 2026 revenue falls 20% to $39.6 million; posts first profitable quarter
Amarin reported third-quarter 2026 total net revenue of $39.6 million, down 20% from $49.7 million a year earlier, driven by a 30% decline in U.S. VASCEPA sales. The company reported net income of $245 thousand, compared with a net loss of $7.7 million in the same quarter of 2025, and said it is working with Barclays as its exclusive financial advisor on efforts to maximize shareholder value.
Key points
- Q3 2026 total net revenue was $39.6 million, down 20% from $49.7 million; U.S. product revenue fell 30% to $28.5 million.
- Q3 2026 net income was $245 thousand, versus a net loss of $7.7 million in Q3 2025; nine-month net loss narrowed to $17.9 million from $37.6 million.
- Cash, cash equivalents and short-term investments were $323.4 million at September 30, 2026, and the company reported no debt.
- Amarin is working with Barclays, its exclusive financial advisor, on efforts to maximize shareholder value.
The filing
Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.